Anti-PD-L1 Checkpoint Inhibitors

Immune checkpoint inhibitors targeting PD-L1 (the ligand for PD-1). Used in NSCLC, urothelial cancer, and triple-negative breast cancer.

HCPCS J-codes in this class (3)

Code Description
J9022 Inj, atezolizumab,10 mg
J9023 Injection, avelumab, 10 mg
J9034 Inj., bendeka 1 mg